Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 7 studies | 32% ± 17% | |
type I pneumocyte | 3 studies | 19% ± 3% | |
goblet cell | 3 studies | 22% ± 5% | |
basal cell | 3 studies | 30% ± 15% |
Insufficient scRNA-seq data for expression of TMEM30B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 6083.86 | 653 / 653 | 98% | 130.48 | 592 / 605 |
prostate | 98% | 1987.60 | 241 / 245 | 99% | 91.58 | 497 / 502 |
pancreas | 100% | 2456.48 | 328 / 328 | 96% | 55.71 | 171 / 178 |
lung | 96% | 1377.44 | 554 / 578 | 98% | 56.13 | 1129 / 1155 |
stomach | 88% | 2957.58 | 315 / 359 | 97% | 48.21 | 278 / 286 |
breast | 81% | 1148.88 | 370 / 459 | 96% | 52.56 | 1072 / 1118 |
bladder | 62% | 1735.43 | 13 / 21 | 94% | 46.96 | 474 / 504 |
intestine | 52% | 1709.36 | 501 / 966 | 98% | 49.95 | 518 / 527 |
esophagus | 49% | 1054.78 | 713 / 1445 | 98% | 61.01 | 179 / 183 |
ovary | 39% | 237.23 | 71 / 180 | 96% | 34.04 | 412 / 430 |
liver | 82% | 617.91 | 185 / 226 | 46% | 11.65 | 186 / 406 |
kidney | 94% | 1087.15 | 84 / 89 | 16% | 10.02 | 140 / 901 |
uterus | 23% | 169.50 | 39 / 170 | 85% | 46.28 | 388 / 459 |
ureter | 0% | 0 | 0 / 0 | 100% | 37.57 | 1 / 1 |
blood vessel | 97% | 2132.68 | 1290 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 44.44 | 43 / 45 |
skin | 73% | 1040.88 | 1319 / 1809 | 2% | 0.41 | 10 / 472 |
adipose | 66% | 582.47 | 797 / 1204 | 0% | 0 | 0 / 0 |
adrenal gland | 42% | 242.31 | 109 / 258 | 1% | 0.70 | 3 / 230 |
heart | 18% | 95.94 | 157 / 861 | 0% | 0 | 0 / 0 |
muscle | 2% | 10.67 | 18 / 803 | 0% | 0 | 0 / 0 |
brain | 2% | 11.86 | 51 / 2642 | 0% | 0 | 0 / 705 |
peripheral blood | 0% | 0.62 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
GO_0140331 | Biological process | aminophospholipid translocation |
GO_0045332 | Biological process | phospholipid translocation |
GO_0015917 | Biological process | aminophospholipid transport |
GO_0070863 | Biological process | positive regulation of protein exit from endoplasmic reticulum |
GO_1990531 | Cellular component | phospholipid-translocating ATPase complex |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
GO_0015247 | Molecular function | aminophospholipid flippase activity |
Gene name | TMEM30B |
Protein name | Cell cycle control protein 50B (P4-ATPase flippase complex beta subunit TMEM30B) (Transmembrane protein 30B) |
Synonyms | CDC50B |
Description | FUNCTION: Accessory component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules. The beta subunit may assist in binding of the phospholipid substrate (Probable). Can mediate the export of alpha subunits ATP8A1, ATP8B1, ATP8B2 and ATP8B4 from the ER to the plasma membrane. . |
Accessions | Q3MIR4 ENST00000555868.2 |